75 related articles for article (PubMed ID: 12168947)
1. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer.
Korpela J; Salminen E
Anticancer Res; 2002; 22(2B):1337-40. PubMed ID: 12168947
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Wenzel C; Locker GJ; Pluschnig U; Zielinski CC; Rudas M; Oberhuber G; Gnant MF; Taucher S; Jakesz R; Steger GG
Cancer Chemother Pharmacol; 2002 Aug; 50(2):155-9. PubMed ID: 12172982
[TBL] [Abstract][Full Text] [Related]
5. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
6. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
8. Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer.
Syvanen K; Ekholm E; Anttila K; Salminen E
Anticancer Res; 2003; 23(2C):1869-73. PubMed ID: 12820471
[TBL] [Abstract][Full Text] [Related]
9. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
12. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
14. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients.
Ekholm E; Rantanen V; Bergman M; Vesalainen R; Antila K; Salminen E
Anticancer Res; 2000; 20(3B):2045-8. PubMed ID: 10928149
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
19. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
20. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]